A condition may be “rare,” but no person should feel invisible.
At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.
Today, we stand with patients, families, advocates, and researchers working to increase awareness and accelerate progress.
JYMed Peptide Secures FDA Completeness Assessment for Second Semaglutide DMF
JYMed Peptide’s New Semaglutide DMF No. 041090 Listed as “Available for Reference” by the U.S. FDA JYMed Peptide...





0 Comments